assessment of short preoperative endocrine therapy in the adapt and adaptcycle trials
Published 2 years ago • 186 plays • Length 4:02Download video MP4
Download video MP3
Similar videos
-
4:17
impact of age, rs and ofs on endocrine response to short preoperative et
-
1:41
adapt trial: endocrine ribociclib vs. chemotherapy in hr /her2- early breast cancer
-
2:43
adaptcycle: adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus che...
-
0:42
role of endocrine therapy in early-stage hr-positive breast cancer
-
3:11
a correlative analysis of coralleen: preoperative ribociclib letrozole vs chemo in hr /her2- bc
-
0:55
cambria-1: camizestrant vs standard endocrine therapy in breast cancer
-
0:35
duration of endocrine therapy in early breast cancer
-
1:30
exploring endocrine therapy innovations for high-risk hormone receptor-positive breast cancer
-
1:38
unanswered questions in the use of adjuvant therapy in early breast cancer
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
8:18
endocrine therapy in premenopausal women with hr breast cancer
-
2:55
e2112: endocrine therapy plus entinostat in hr advanced breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
4:03
monarche 4-year: abemaciclib endocrine therapy for hr , her2-, node-positive, high-risk early bc
-
1:20
updated safety findings of pf-07220060 and endocrine therapy in hr /her2- breast cancer
-
1:43
evaluating endocrine therapy in pre-menopausal women with breast cancer
-
1:05
clinical impact of positive trial
-
3:46
outcomes from adapt-hr-/her2 evaluating dual her2 blockade